Alcon Acquired by Novartis
On December 15, 2010, Novartis (NYSE: NVS) agreed to acquire the remaining shares of Alcon, Inc. (NYSE: ACL) it doesn't currently own for $168 per share.
The merger consideration will be comprised of a combination of Novartis shares and, if necessary, a cash contingent value amount to result in a total value of $168 per share.
Upon completion of the merger, Alcon will become the second largest division within Novartis. CIBA VISION and select Novartis ophthalmic medicines will be integrated into Alcon, forming an organization with more than $8.7 billion in sales covering over 70 percent of the eye care segment.
The merger consideration will be comprised of a combination of Novartis shares and, if necessary, a cash contingent value amount to result in a total value of $168 per share.
Upon completion of the merger, Alcon will become the second largest division within Novartis. CIBA VISION and select Novartis ophthalmic medicines will be integrated into Alcon, forming an organization with more than $8.7 billion in sales covering over 70 percent of the eye care segment.
View Older Stories View More Recent Stories
-
VisionCare Ophthalmic Technologies Expands Executive Team
-
ThromboGenics Business Update H1 2015
-
ThromboGenics Business Update H1 2015
-
Ignyta Announces Second Quarter 2015 Company Highlights and Financial Results
-
Acucela Hires Dr. Lukas Scheibler as Executive Vice President of Translational Medicine
-
Ohr Pharmaceutical (OHRP) Appoints New CEO
-
Ohr Pharmaceutical Promotes Jason S. Slakter, MD to Chief Executive Officer
-
EPGL and Novartis to Enter Discussions
-
EPGL and Novartis to Enter Discussions
-
Sierra Monitor Corporation Announces Financial Results for the Second Quarter Ended June 30, 2015
-
Ignyta Boosts Leadership Capacity with Appointment of Bernard Parker as Chief Commercial Officer
-
Inotek Pharmaceuticals Appoints Dr. Cadmus Collins Rich as Vice President, Medical Affairs and Clinical Development
-
Novartis (NVS) Tops Q2 EPS by 3c
-
Alcon (NVS) Receives CE Mark for AcrySof IQ Aspheric IOL with UltraSert
-
Innocoll AG Appoints Jose Carmona as Chief Financial Officer
-
Alcon launches new hydrogen peroxide-based contact lens cleaning & disinfecting solution in the US
-
Sebacia Announces New Vice President, Engineering and Program Management
-
Alcon Laboratories Honors KLLM Transport/FFE as Global Partner of the Year
-
Marshall B. Ketchum University Announces Its 2015 V-Award Honorees for the Fifth Annual MBKU Gala
-
Alcon (NVS) Receives CE Mark for AcrySof IQ PanOptix Trifocal IOL
-
Acelity L.P. Inc. Appoints Two New Members to Its Board of Directors
-
ThromboGenics Q1 2015 Business Update
-
Fishman Corporation Named 2014 Alcon Supplier of Excellence
-
Alcon Study Reveals Nearly Half of Americans Would Avoid Reading Glasses If They Knew It Made Them Look Older
-
Fishman Corporation Named 2014 Alcon Supplier of Excellence
-
Aerie Pharmaceuticals Elects Richard Croarkin to the Company’s Board of Directors
-
ThromboGenics Starts Evaluating JETREA(r) for the Treatment of Retinal Vein Occlusion (RVO)
-
VisionCare Ophthalmic Technologies Names Wolfgang Tolle Chief Executive Officer
-
ThromboGenics and VIB launch New Oncology Company
-
Icon Bioscience Reports Successful Outcomes of Phase 3 Study of IBI-10090, a Novel Sustained Release Drug Being Developed to Treat Inflammation Associated with Cataract Surgery
-
Jeff Evanson Joins Navigant Life Sciences Practice as Managing Director
-
OASIS Study Clarification with regard to number of ERM Patients recruited
-
Jeremy Bloom and Rand Fishkin to Keynote iPharma 2015: CBI's 14th Annual Marketing Innovation Summit
-
ThromboGenics Announces Positive Topline Results from OASIS Study
-
Cynapsus Therapeutics Reports 2014 Annual Results
-
Two Global Directors Of Novartis And Alcon File Individual And Collective Gender Discrimination Case
-
ThromboGenics' JETREA(r) Gains Approval in Brazil
-
ThromboGenics Full Year 2014 Business Update
-
Galderma Poised for Growth in the U.S. with Holistic Approach to Skin Health
-
ThromboGenics Appoints Dr Joseph Markoff as Scientific Advisor
-
Alcon (NVS) Reports RTH258 Phase 2 Met Primary Endpoint
-
Akorn Confirms Generic Durezol(R) Patent Challenge
-
Novartis AG (NVS) Novartis Names New Division Leaders for Sandoz, Alcon
-
Perrigo (PRGO) Names CEO Papa as Chairman; Announces Director Slate
-
Novartis (NVS) Announces $5B Buyback Plan; Updates on Long-Term Expectations
-
Novartis' (NVS) Alcon Receives Positive CHMP Opinion for Jetrea as VMT Treatment
-
Novartis' (NVS) Unit Gets Exclusive Rights to Ocriplasmin Outside the U.S.
-
Novartis (NVS) Misses Q3 EPS by 6c, Sales Miss Expectations, Offers Q4 Outlook
-
Novartis (NVS) Updates on Long-Term Strategy; Comments on Plans for Alcon
-
Top 10 News Items 12/13-12/17: $858B Tax-Cut Bill Signed; Best Buy Tanks on Concerning Q3 Results; Visa, MasterCard Tumble As Durbin Strikes Back

